Clinical Trial Update: The Use of Eltrombopag Post HSCT in BMFD [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial evaluating eltrombopag after hematopoietic stem cell transplantation for bone marrow failure has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Marrow Failure

Drugs mentioned

• Promacta (eltrombopag)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Stem Cell Transplant Complications | Phase 2, Phase 3 | Status: COMPLETED